Changes in mRNA/protein expression and signaling pathways in in vivo passaged mouse ovarian cancer cells

The cure rate for late stage epithelial ovarian cancer (EOC) has not significantly improved over several decades. New and more effective targets and treatment modalities are urgently needed. RNA-seq analyses of a syngeneic EOC cell pair, representing more and less aggressive tumor cells in vivo were conducted. Bioinformatics analyses of the RNA-seq data and biological signaling and function studies have identified new targets, such as ZIP4 in EOC. Many up-regulated tumor promoting signaling pathways have been identified which are mainly grouped into three cellular activities: 1) cell proliferation and apoptosis resistance; 2) cell skeleton and adhesion changes; and 3) carbohydrate metabolic reprograming. Unexpectedly, lipid metabolism has been the major down-regulated signaling pathway in the more aggressive EOC cells. In addition, we found that hypoxic responsive genes were at the center stage of regulation and detected functional changes were related to cancer stem cell-like activities. Moreover, our genetic, cellular, biochemical, and lipidomic analyses indicated that cells grown in 2D vs. 3D, or attached vs. suspended had dramatic changes. The important clinical implications of peritoneal cavity floating tumor cells are supported by the data proved in this work. Overall, the RNA-seq data provide a landscape of gene expression alterations during tumor progression.

[1]  M. Rinaldi,et al.  GLUT 1 receptor expression and circulating levels of fasting glucose in high grade serous ovarian cancer , 2018, Journal of cellular physiology.

[2]  U. Ray,et al.  Aberrant lipid metabolism in cancer cells – the role of oncolipid‐activated signaling , 2018, The FEBS journal.

[3]  Ho-Yyoung Lee,et al.  Oncogene-Driven Metabolic Alterations in Cancer , 2017, Biomolecules & therapeutics.

[4]  A. Jemal,et al.  Cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.

[5]  Haiyan Zhang,et al.  High ALDH activity defines ovarian cancer stem-like cells with enhanced invasiveness and EMT progress which are responsible for tumor invasion. , 2018, Biochemical and biophysical research communications.

[6]  A. Jemal,et al.  Factors That Contributed to Black-White Disparities in Survival Among Nonelderly Women With Breast Cancer Between 2004 and 2013. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  M. Knight,et al.  Deconstruction of a Metastatic Tumor Microenvironment Reveals a Common Matrix Response in Human Cancers. , 2018, Cancer discovery.

[8]  M. Matzuk,et al.  CRISPR/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity , 2017, Scientific Reports.

[9]  W. Woodward,et al.  Effect of statins on breast cancer recurrence and mortality: a review , 2017, Breast cancer.

[10]  K. Odunsi Immunotherapy in ovarian cancer. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  C. Denkert,et al.  High-grade ovarian serous carcinoma patients exhibit profound alterations in lipid metabolism , 2017, Oncotarget.

[12]  I. Shih,et al.  The novel ZIP4 regulation and its role in ovarian cancer , 2017, Oncotarget.

[13]  Changxiu Wang,et al.  Clinical significance and biological role of Wnt10a in ovarian cancer , 2017, Oncology letters.

[14]  K. O'Byrne,et al.  Targeting the cancer stem cell marker, aldehyde dehydrogenase 1, to circumvent cisplatin resistance in NSCLC , 2017, Oncotarget.

[15]  M. Stack,et al.  Complex Determinants of Epithelial: Mesenchymal Phenotypic Plasticity in Ovarian Cancer , 2017, Cancers.

[16]  G. Rice,et al.  The Crosstalk between Ovarian Cancer Stem Cell Niche and the Tumor Microenvironment , 2017, Stem cells international.

[17]  M. Ruchała,et al.  Genomic markers of ovarian adenocarcinoma and its relevancy to the effectiveness of chemotherapy , 2017, Oncology letters.

[18]  Yan Xu,et al.  lpa regulates sox9 in ovarian cancer cells , 2017 .

[19]  J. Lang,et al.  Statin use and survival outcomes in endocrine-related gynecologic cancers: A systematic review and meta-analysis , 2017, Oncotarget.

[20]  U. Cavallaro,et al.  Ovarian cancer stem cells: still an elusive entity? , 2017, Molecular Cancer.

[21]  K. Busam,et al.  The NF1 gene in tumor syndromes and melanoma , 2017, Laboratory Investigation.

[22]  I. Vergote,et al.  Ovarian cancer and the immune system , 2017, Gynecologic oncology reports.

[23]  A. Jemal,et al.  Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.

[24]  I. McNeish,et al.  CRISPR/Cas9-Mediated Trp53 and Brca2 Knockout to Generate Improved Murine Models of Ovarian High-Grade Serous Carcinoma. , 2016, Cancer research.

[25]  H. Donninger,et al.  Ras signaling through RASSF proteins. , 2016, Seminars in cell & developmental biology.

[26]  Yuquan Wei,et al.  Tumor microenvironment: The culprit for ovarian cancer metastasis? , 2016, Cancer letters.

[27]  K. Hayashi,et al.  WNT7A Regulation by miR-15b in Ovarian Cancer , 2016, PloS one.

[28]  J. Ajduković HIF-1--a big chapter in the cancer tale. , 2016, Experimental oncology.

[29]  Zhenwen Zhao,et al.  The Lipidomic Analyses in Low and Highly Aggressive Ovarian Cancer Cell Lines , 2016, Lipids.

[30]  H. Katabuchi,et al.  CD44 variant 6 is correlated with peritoneal dissemination and poor prognosis in patients with advanced epithelial ovarian cancer , 2015, Cancer science.

[31]  Zhuling Yang,et al.  Musashi-1 Expression is a Prognostic Factor in Ovarian Adenocarcinoma and Correlates with ALDH-1 Expression , 2015, Pathology & Oncology Research.

[32]  Yan Xu,et al.  The microenvironment reprograms circuits in tumor cells , 2015, Molecular & cellular oncology.

[33]  Yan Xu,et al.  Anoikis resistance is a critical feature of highly aggressive ovarian cancer cells , 2014, Oncogene.

[34]  Jingru Zhang,et al.  The expression of VEGF and Dll4/Notch pathway molecules in ovarian cancer. , 2014, Clinica chimica acta; international journal of clinical chemistry.

[35]  C. Denkert,et al.  Overexpression of the epithelial cell adhesion molecule is associated with a more favorable prognosis and response to platinum-based chemotherapy in ovarian cancer , 2014, Journal of gynecologic oncology.

[36]  Zhihong Zhang,et al.  Cancer stem cells, epithelial-mesenchymal transition, and drug resistance in high-grade ovarian serous carcinoma. , 2013, Human pathology.

[37]  E. Levanon,et al.  Human housekeeping genes, revisited. , 2013, Trends in genetics : TIG.

[38]  Haixu Tang,et al.  A new method for stranded whole transcriptome RNA-seq. , 2013, Methods.

[39]  J. Pouysségur,et al.  Disrupting proton dynamics and energy metabolism for cancer therapy , 2013, Nature Reviews Cancer.

[40]  R. Berkowitz,et al.  Characterization of aldehyde dehydrogenase isozymes in ovarian cancer tissues and sphere cultures , 2012, BMC Cancer.

[41]  K. Green,et al.  Desmoplakin regulates desmosome hyperadhesion , 2011, The Journal of investigative dermatology.

[42]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[43]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[44]  G. Sandusky,et al.  Group VIA phospholipase A2 in both host and tumor cells is involved in ovarian cancer development , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[45]  M. A. Khan,et al.  Association of lipid metabolism with ovarian cancer. , 2010, Current oncology.

[46]  H. An,et al.  Prognostic significance of Notch 3 gene expression in ovarian serous carcinoma , 2010, Cancer science.

[47]  Tian-Li Wang,et al.  Jagged1 Expression Regulated by Notch3 and Wnt/β-catenin Signaling Pathways in Ovarian Cancer , 2010, Oncotarget.

[48]  Mark D. Robinson,et al.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..

[49]  H. Frierson,et al.  PRK1 distribution in normal tissues and carcinomas: overexpression and activation in ovarian serous carcinoma. , 2009, Human pathology.

[50]  M. Fong,et al.  Ovarian cancer mouse models: a summary of current models and their limitations , 2009, Journal of ovarian research.

[51]  Hanna Y. Irie,et al.  Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment , 2009, Nature.

[52]  Dongmei Wang,et al.  Lysophosphatidic acid stimulates cell migration, invasion, and colony formation as well as tumorigenesis/metastasis of mouse ovarian cancer in immunocompetent mice , 2009, Molecular Cancer Therapeutics.

[53]  Robert A. Harris,et al.  Pyruvate Dehydrogenase Complex Activity Controls Metabolic and Malignant Phenotype in Cancer Cells* , 2008, Journal of Biological Chemistry.

[54]  Curt Balch,et al.  Identification and characterization of ovarian cancer-initiating cells from primary human tumors. , 2008, Cancer research.

[55]  P. Shaw,et al.  Epithelial-stromal interaction increases cell proliferation, survival and tumorigenicity in a mouse model of human epithelial ovarian cancer. , 2008, Gynecologic oncology.

[56]  C. Carlberg,et al.  Meta-analysis of primary target genes of peroxisome proliferator-activated receptors , 2007, Genome Biology.

[57]  D. Stoffer,et al.  PI3K is negatively regulated by PIK3IP1, a novel p110 interacting protein. , 2007, Biochemical and biophysical research communications.

[58]  S. Mok,et al.  Hypoxia enhances lysophosphatidic acid responsiveness in ovarian cancer cells and lysophosphatidic acid induces ovarian tumor metastasis in vivo. , 2006, Cancer research.

[59]  D. Katafiasz,et al.  Carboxyl Terminus of Plakophilin-1 Recruits It to Plasma Membrane, whereas Amino Terminus Recruits Desmoplakin and Promotes Desmosome Assembly* , 2006, Journal of Biological Chemistry.

[60]  M. Clarke,et al.  Stem Cells and Cancer: Two Faces of Eve , 2006, Cell.

[61]  Hung,et al.  Enhanced c-erbB2 / neu Expression in Human Ovarian Cancer Cells Correlates with More Severe Malignancy That Can Be Suppressed by EIA 1 , 2006 .

[62]  A. Becker,et al.  GLUT1 mRNA and Protein Expression in Ovarian Borderline Tumors and Cancer , 2004, Oncology.

[63]  I. Weissman,et al.  Stem cells, cancer, and cancer stem cells , 2001, Nature.

[64]  J L Pace,et al.  Development of a syngeneic mouse model for events related to ovarian cancer. , 2000, Carcinogenesis.

[65]  C. Dinney,et al.  Highly metastatic human prostate cancer growing within the prostate of athymic mice overexpresses vascular endothelial growth factor. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[66]  Mike Wilson,et al.  Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[67]  M. Hung,et al.  Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. , 1993, Cancer research.

[68]  I. Fidler,et al.  Selection of successive tumour lines for metastasis. , 1973, Nature: New biology.